Tag Archives: another

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class first

AstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. Tuesday, the companies said their PARP inhibitor had topped placebo at staving off progression of tough-to-treat pancreatic cancer in patients with germline BRCA-mutated forms of the disease. The phase 3 study, dubbed POLO, examined Lynparza in… Read More »